Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation

https://doi.org/10.20996/1819-6446-2021-01-01

Full Text:

Abstract

Aim. To study the prognostic value of the ORACLE risk score for assessing the risk of bleeding in patients with acute coronary syndrome (ACS) undergoing anticoagulants for atrial fibrillation using the combined database of the ORACLE II and RECORD 3 registers.

Material and methods. This analysis included patients with ACS from 2 observational studies: ORACLE II (ObseRvation after Acute Coronary syndrome for deveLopment of trEatment options; n=1803) and the RECORD-3 register (n=2370). In total, the database included 4173 patients, of which 246 (6.08%) received oral anticoagulants for atrial fibrillation. The mean age of patients was 64.7±11.9 years, 2493 (59.7%) were men. Hemorrhagic risk was assessed using the ORACLE, CRUSADE, ORBIT, and HAS-BLED risk score.

Results. Patients receiving anticoagulant therapy were older (69.9±11.3 years and 64.0±12.2 years, p<0.001). Among these patients there was a larger proportion of women, and a smaller proportion of patients with ACS with ST elevation, they were more likely to have chronic heart failure, chronic kidney disease, history of stroke. Among patients receiving anticoagulants and included in the ORACLE study, the frequency of percutaneous coronary intervention was higher than in patients included in the RECORD study. In the joint database, 71 significant bleeding was recorded during the hospitalization period – 64 (1.7%) in patients without anticoagulants and 7 (2.8%) among patients taking anticoagulants (p=0.06). Over 6 months, among patients who did not receive anticoagulants, there were 97 cases of bleeding (in 2.6% of patients), in the group of patients receiving anticoagulants – 12 cases of bleeding (4.9%) – the differences in frequency were significant (p=0.029). The ORACLE risk score had the greatest prognostic value (area under the ROC curve 0.874±0.0416, sensitivity 82.7%, specificity 79.1%). The predictive value of the HAS-BLED risk score was slightly lower (area under the ROC curve 0.710±0.0360, sensitivity 63.2%, specificity 56.8%). The value of the CRUSADE risk score (area under the ROC curve 0.612±0.0269, sensitivity 53.7%, specificity 59.5%) and ORBIT risk score (area under the ROC curve 0.606±0.0457, sensitivity 62.5%, specificity 58.3%) were lower (p<0.001 for all scales).

Conclusion. The use of the ORACLE bleeding risk score can be recommended for patients with ACS requiring anticoagulant therapy.

About the Authors

V. A. Brazhnik
City clinical hospital №51; Central State Medical Academy of Department of Presidential Affairs
Russian Federation

Victoria A. Brazhnik

Москва

eLibrary SPIN: 5627-9617



L. O. Minushkina
Central State Medical Academy of Department of Presidential Affairs
Russian Federation

Larisa O. Minushkina

Москва

eLibrary SPIN: 3654-8920



A. D. Erlikh
City Clinical Hospital №29 n.a. N.E. Bauman
Russian Federation

Alexey D. Erlikh

Москва

eLibrary SPIN: 4697-0822



E. D. Kosmacheva
Kuban State Medical University
Russian Federation

Elena D. Kosmacheva

Krasnodar

eLibrary SPIN: 5277-2982



M. A. Chichkova
Central State Medical Academy of Department of Presidential Affairs
Russian Federation

Marina A. Chichkova

Москва

eLibrary SPIN: 5244-5358



N. R. Khasanov
Kazan State Medical University
Russian Federation

Niyaz R. Khasanov

Kazan

eLibrary SPIN: 2501-3397



D. A. Zateyshchikov
City clinical hospital №51; Central State Medical Academy of Department of Presidential Affairs
Russian Federation

Dmitry A. Zateyshchikov

Москва

eLibrary SPIN: 1694-3031



References

1. Brazhnik V.A., Minushkina L.O., Guliev R.R., et al. Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II. Russ J Cardiol. 2019;24(3):7-16 (In Russ.) DOI:10.15829/1560-4071-2019-3-7-16.

2. Erlikh A.D., Gratsiansky N.A. Registry of Acute Coronary Syndromes "RECORD-3". Characteristics of Patients and Treatment During Initial Hospitalization. Kardiologiia. 2016;56(4):16-24 (In Russ.) DOI:10.18565/cardio.2016.4.16-24.

3. Subherwal S., Bach R.G., Chen A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873-82. DOI:10.1161/CIRCULATIONAHA.108.828541.

4. O'Brien E.C., Simon D.N., Thomas L.E., et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258-64. DOI:10.1093/eurheartj/ehv476.

5. Pisters R., Lane D.A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093- 100. DOI:10.1378/chest.10-0134.

6. Fake A.L., Harding S.A., Matsis P.P., Larsen P.D. Pharmacological therapy following acute coronary syndromes in patients with atrial fibrillation: how do we balance ischemic risk with bleeding risk? N Z Med J. 2016;129(1435):39-49.

7. Smith J.G., Wieloch M., Koul S., et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. Euro Intervention. 2012;8(6):672-8. DOI:10.4244/EIJV8I6A105.

8. Castini D., Persampieri S., Sabatelli L., et al. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels. 2019;34(10):1621-30. DOI:10.1007/s00380-019-01405-1.

9. Yoshida R., Ishii H., Morishima I., et al. Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention. J Cardiol. 2019;73(6):479-87. DOI:10.1016/j.jjcc.2018.10.013.

10. Costa F., Tijssen J.G., Ariotti S., et al. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. J Am Heart Assoc. 20157;4(12):pii e002524. DOI:10.1161/JAHA.115.002524.

11. Kharchenko M.S., Erlikh A.D., Gratsianskii N.A. Assessment of the prognostic value of the CRUSADE score in patients with acute coronary syndromes hospitalized in a noninvasive hospital. Kardiologiia. 2012;52(8):27-32 (In Russ).


For citation:


Brazhnik V.A., Minushkina L.O., Erlikh A.D., Kosmacheva E.D., Chichkova M.A., Khasanov N.R., Zateyshchikov D.A. Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2021;17(1):11-15. https://doi.org/10.20996/1819-6446-2021-01-01

Views: 146


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)